ANI Pharmaceuticals Inc. July 1 announced that it has acquired the new drug application for Lithobid (lithium carbonate) extended-release 300 mg tablets from Noven Therapeutics LLC.
Lithobid is indicated in the treatment of manic episodes of bipolar disorder. Total consideration for the product was $12 million, including an $11 million upfront payment and a $1 million future milestone payment, the Baudette, Minn.-based company said.
ANI said it expects to launch Lithobid in July under its own label.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.